Diabetes

Over 10 years, among adherent participants, lifestyle intervention and metformin were effective and cost-effective for diabetes prevention compared with placebo.

Michael Farkouh, MD, Director of Clinical Trials and Associate Professor of Medicine, Mount Sinai School of Medicine, says that there are many strategies to both prevent and control diabetes mellitus, but he notes that obesity prevention is key.

Conventional individualized diabetes self-management education resulted in sustained improvement in self-efficacy and diabetes distress. Short-term improvements in A1C, nutrition, and physical activity were not sustained.

Policy makers should not expect public sector electronic medical record investments to yield substantial short-term improvements in publicly reported measures.

Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.

To act as a catalyst for ideas, partnerships, and collaboration among all stakeholders to provoke thought, innovation, and action to address the cost, productivity, and quality-of-life impact of diabetes, obesity, and related conditions and comorbidities on our society, Joslin Diabetes Center convened Diabetes Innovation for the first time in 2012. Highlights from Diabetes Innovation, which took place on September 23-25 2012, in Arlington, Virginia, are available in a special report published by The American Journal of Managed Care.

The management of type 2 diabetes mellitus (T2DM) remains challenging. Limitations associated with many current therapies include hypoglycemia and weight gain. An increased understanding of the pathophysiology of T2DM has led to the development of incretin-related antihyperglycemic therapies.

The aDCSI without the inclusion of laboratory data performs similarly to the DCSI with laboratory results, and is a good measure of diabetes severity.

The heterogeneous nature of care processes and patients should be taken into account in both the design and evaluation of disease management programs for diabetes.

In this video, Feng Zeng, PhD, Senior Health Economist, MedImpact, discusses how the implementation of copayment reduction in the gap in 2011 influenced adherence measures for oral diabetes medications.

We examined the impact of clinical complexity defined by comorbidity count and illness burden on comprehensive diabetes care, including blood pressure, glycemic, and lipid management.